10x Genomics (NASDAQ:TXG) Given Consensus Recommendation of “Hold” by Brokerages

Shares of 10x Genomics (NASDAQ:TXG) have been given an average recommendation of “Hold” by the sixteen research firms that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have issued a buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $13.6538.

A number of analysts have recently commented on TXG shares. Zacks Research cut 10x Genomics from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 5th. Barclays restated an “overweight” rating and issued a $15.00 price objective (up from $13.00) on shares of 10x Genomics in a research report on Friday, August 8th. Morgan Stanley cut their price objective on 10x Genomics from $18.00 to $17.00 and set an “overweight” rating for the company in a research report on Tuesday, August 12th. Canaccord Genuity Group set a $16.00 price objective on 10x Genomics in a research report on Monday, August 11th. Finally, UBS Group boosted their price target on 10x Genomics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research report on Friday, August 8th.

Insider Activity

In other news, insider Benjamin J. Hindson sold 7,486 shares of the company’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $103,231.94. Following the transaction, the insider owned 440,888 shares of the company’s stock, valued at $6,079,845.52. This represents a 1.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Adam Taich sold 22,315 shares of the company’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $307,723.85. Following the completion of the transaction, the chief financial officer directly owned 309,273 shares in the company, valued at approximately $4,264,874.67. This trade represents a 6.73% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 39,149 shares of company stock valued at $539,865 in the last quarter. Insiders own 9.39% of the company’s stock.

Hedge Funds Weigh In On 10x Genomics

Several large investors have recently modified their holdings of the business. Lancaster Investment Management acquired a new position in shares of 10x Genomics in the 3rd quarter valued at $7,269,000. Grant Private Wealth Management Inc acquired a new position in shares of 10x Genomics in the 3rd quarter valued at $141,000. Mirador Capital Partners LP lifted its stake in shares of 10x Genomics by 2.2% in the 3rd quarter. Mirador Capital Partners LP now owns 81,182 shares of the company’s stock valued at $949,000 after purchasing an additional 1,739 shares during the last quarter. Aaron Wealth Advisors LLC acquired a new position in 10x Genomics during the 3rd quarter worth about $462,000. Finally, Corient Private Wealth LLC acquired a new position in 10x Genomics during the 2nd quarter worth about $595,000. Institutional investors and hedge funds own 84.68% of the company’s stock.

10x Genomics Price Performance

10x Genomics stock opened at $12.07 on Thursday. The stock has a market capitalization of $1.50 billion, a PE ratio of -17.24 and a beta of 2.05. 10x Genomics has a 12 month low of $6.78 and a 12 month high of $20.83. The business has a 50 day simple moving average of $13.05 and a 200-day simple moving average of $11.03.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.63. The business had revenue of $172.91 million during the quarter, compared to analysts’ expectations of $139.36 million. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The business’s revenue was up 12.9% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.32) earnings per share. 10x Genomics has set its Q3 2025 guidance at EPS. On average, equities research analysts anticipate that 10x Genomics will post -1.43 EPS for the current fiscal year.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.